IP Library › Granted Patent US 7,429,387
Granted Patent B2
US 7,429,387 · App. 11/077,895 · Granted Sep 30, 2008

Use of botulinum toxin therapy for treatment of recalcitrant voiding dysfunction

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,429,387
App. No.
11/077,895
Granted
Sep 30, 2008
Kind
B2
Abstract

The present invention related to methods for treating neurological-urological conditions. This is accomplished by administration of at least one neurotoxin.

Claims (11)

1. A method for treating a recalcitrant voiding dysfunction, the method comprising the step of injecting a botulinum toxin to a lateral bladder wall of a patient, thereby treating the recalcitrant voiding dysfunction.

2. The method of claim 1 , wherein the patent is a human.

3. The method of claim 1 , wherein the patient is a human female.

4. The method of claim 1 , wherein the patient is a human male.

5. The method of claim 1 , wherein the botulinum toxin is a botulinum toxin type A.

6. The method of claim 1 , wherein a symptom of the recalcitrant voiding dysfunction is urinary incontinence.

7. A method for treating a recalcitrant voiding dysfunction, the method comprising the step of injecting a therapeutically effective amount of a botulinum toxin type A to a lateral bladder wall a patient, thereby treating the recalcitrant voiding dysfunction.

8. The method of claim 7 , wherein the botulinum toxin type A is injected in the amount up to 2500 units.

9. The method of claim 7 , wherein the therapeutically effective amount of botulinum toxin type A is about 1.4 IU/kg to 17.1 IU/kg of botulinum toxin type A.

10. The method of claim 7 , wherein the therapeutically effective amount of botulinum toxin type A is 200 IU of botulinum toxin type A.

11. The method of claim 7 , wherein the therapeutically effective amount of botulinum toxin type A is 400 IU of botulinum toxin type A.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 5, 2015
From: THE REGENTS OF THE UNIVERSITY OF COLORADO
To: ALLERGAN, INC.
Reel/Frame 036260/0570 →